Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Blackrock Technology and Private Equity Term Tru (BTX)

Blackrock Technology and Private Equity Term Tru (BTX)
6.21 x 400 6.55 x 100
Post-market by (Cboe BZX)
6.29 +0.03 (+0.48%) 04/01/25 [NYSE]
6.21 x 400 6.55 x 100
Post-market 6.35 +0.06 (+0.95%) 17:01 ET
Quote Overview for Tue, Apr 1st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
6.15
Day High
6.34
Open 6.19
Previous Close 6.26 6.26
Volume 962,200 962,200
Avg Vol 844,020 844,020
Stochastic %K 26.69% 26.69%
Weighted Alpha -23.80 -23.80
5-Day Change -0.27 (-4.12%) -0.27 (-4.12%)
52-Week Range 6.06 - 8.31 6.06 - 8.31
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 12,059
  • Shares Outstanding, K 58,826
  • Annual Sales, $ 40,691 K
  • Annual Income, $ -122,310 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 4.61
  • Price/Sales 32.98
  • Price/Cash Flow N/A
  • Price/Book 0.80
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.33
  • Most Recent Earnings $-0.17 on 07/01/22
  • Next Earnings Date 11/08/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.06 +3.80%
on 03/31/25
Period Open: 7.11
7.25 -13.24%
on 03/03/25
-0.82 (-11.53%)
since 02/28/25
3-Month
6.06 +3.80%
on 03/31/25
Period Open: 7.44
8.31 -24.29%
on 01/21/25
-1.15 (-15.46%)
since 12/31/24
52-Week
6.06 +3.80%
on 03/31/25
Period Open: 8.11
8.31 -24.29%
on 01/21/25
-1.82 (-22.44%)
since 04/01/24

Most Recent Stories

More News
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from...

BTX : 6.29 (+0.48%)
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company...

BTX : 6.29 (+0.48%)
Brooklyn ImmunoTherapeutics Announces Board Changes

SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company...

BTX : 6.29 (+0.48%)
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting

SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company...

BTX : 6.29 (+0.48%)
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q

SAN DIEGO, May 27, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring...

BTX : 6.29 (+0.48%)
Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines

Company has expanded team with scientific hires who hold research expertise in stem cells, synthetic RNA, nanoparticle delivery systems and immunology...

BTX : 6.29 (+0.48%)
Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on...

BTX : 6.29 (+0.48%)
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement

NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on...

BTX : 6.29 (+0.48%)
Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on...

BTX : 6.29 (+0.48%)
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio

NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on...

BTX : 6.29 (+0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

BTX Dividends

Date Value
02/14/25 $0.0870
01/15/25 $0.0870
12/16/24 $0.0870
11/15/24 $0.0860
10/15/24 $0.0860
09/16/24 $0.0870
08/15/24 $0.0880
07/15/24 $0.0880
06/14/24 $0.0890
05/14/24 $0.0440
04/12/24 $0.0440
03/14/24 $0.0440
02/14/24 $0.0450
01/11/24 $0.0450
12/14/23 $0.0450
11/14/23 $0.0450
10/13/23 $0.0460
09/14/23 $0.0700
08/14/23 $0.0700
07/13/23 $0.0700
06/14/23 $0.0700
05/12/23 $0.0700
04/13/23 $0.0700
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies